SangWook Yoon

SangWook Yoon

Auto-generated profile, based on publicly available information

SangWook Yoon

CELLTRION Healthcare Co., Ltd, Incheon, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
GDGeert R. D’Haens
Geert R. D’Haens
WRWalter Reinisch
Walter Reinisch
SSStefan Schreiber
Stefan Schreiber
FCFraser Cummings
Fraser Cummings
PIPeter M. Irving
Peter M. Irving
SBShomron Ben-Horin
Shomron Ben-Horin
Background and Objective Whether benefits and risks of intravenous (IV) infliximab combotherapy with immunosuppressants versus infliximab monotherapy apply to subcutaneous (SC) infliximab is unknown. This post hoc analysis of a pivotal randomised CT-P13 SC 1.6 trial aimed to compare SC infliximab monotherapy with combotherapy in inflammatory bowel disease (IBD). Methods Biologic-naïve patients with active Crohn’s disease or ulcerative colitis received CT-P13 IV 5 mg/kg at Week (W) 0 and 2 (dose-loading phase). At W6, patients were randomised (1:1) to receive CT-P13 SC 120 or 240 mg (patients < 80 or ≥ 80 kg) every 2 weeks until W54 (maintenance phase), or to continue CT-P13 IV every 8 weeks until switching to CT-P13 SC from W30. The primary endpoint—non-inferiority of trough serum concentrations—was assessed at W22. We report a post hoc analysis comparing pharmacokinetic, efficacy, safety and immunogenicity outcomes up to W54 for patients randomised to CT-P13 SC, stratified by concomitant immunosuppressant use. Results Sixty-six patients were randomised to CT-P13 SC (37 monotherapy, 29 combotherapy). At W54, there were no significant differences in the proportions of patients achieving target exposure (5 µg/mL; 96.6% monotherapy vs 95.8% combotherapy; p > 0.999) or meeting efficacy or biomarker outcomes including clinical remission (62.9% vs 74.1%; p = 0.418). Monotherapy and combotherapy groups had comparable immunogenicity (anti-drug antibodies [ADAs]: 65.5% vs 48.0% [p = 0.271], neutralising antibodies [in ADA-positive patients]: 10.5% vs 16.7% [p = 0.630], respectively). Conclusions Pharmacokinetics, efficacy and immunogenicity were potentially comparable between SC infliximab monotherapy and combotherapy in biologic-naïve IBD patients. Trial Registration ClinicalTrials.gov: NCT02883452. Graphical Abstract

3 June 2022 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
RARieke Alten
Rieke Alten
YAYoorim An
Yoorim An
DKDong-Hyeon Kim
Dong-Hyeon Kim
SYSangWook Yoon
SangWook Yoon
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet

6 December 2021 in Immunotherapy
Verified
Journal Article
Closed access
Enrico FusaroEnrico Fusaro
Enrico Fusaro
PDPatrick Durez
Patrick Durez
JWJohannes Wohlrab
Johannes Wohlrab
SLSoohyun Lee
Soohyun Lee
SYSangWook Yoon
SangWook Yoon
HMHubert Marotte
Hubert Marotte
Biosimilars can reduce healthcare costs and expand patient access to biologic therapies. Currently, eight adalimumab biosimilars have received regulatory approval from the EMA and/or the US FDA. Fo...

13 January 2022 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
OVOmbretta Viapiana
Ombretta Viapiana
SLSoohyun Lee
Soohyun Lee
SYSangWook Yoon
SangWook Yoon
BFBruno Fautrel
Bruno Fautrel

24 March 2022 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
DCDasom Choi
Dasom Choi
SLSoohyun Lee
Soohyun Lee
SKSeungmin Kim
Seungmin Kim
SYSangwook Yoon
Sangwook Yoon

16 June 2022 in Gastroenterology
Verified
Journal Article
Open access
DBDeborah Baik
Deborah Baik
RARaja Atreya
Raja Atreya
YBYoram Bouhnik
Yoram Bouhnik
DCDaniel Casey
Daniel Casey
MJMinyoung Jang
Minyoung Jang
TKTaek S. Kwon
Taek S. Kwon